Drug intelligence / Profile preview

APRTX-004

Development stage: Preclinical
Lead developer: Aperture Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

APRTX-004 is an antisense oligonucleotide (ASO) currently in preclinical development by Aperture Therapeutics for the treatment of peripheral neuropathy. As an oligonucleotide-based therapeutic, it is designed to selectively modulate the expression of a specific genetic target to address the underlying pathophysiology of nerve damage. While the specific molecular target remains undisclosed by the developer, the program is part of Aperture's broader pipeline focusing on first-in-class ASO molecules for neurological and neurodegenerative conditions.

Beyond the preview

Go deeper on APRTX-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APRTX-004.

Explore the full profile